Black Diamond Cuts Programs, Workforce to Save Funding for Prospective Lung Cancer Therapy

MT Newswires Live

Oct 08, 2024

Black Diamond Therapeutics (BDTX) disclosed plans Monday to restructure business to focus on advancing its BDTX-1535 lead program candidate and extending its financial resources into Q2 2026.

Black Diamond said it expects to report initial results from phase 2 testing of BDTX-1535, a treatment for a form of recurrent non-small cell lung cancer characterized by epidermal growth factor receptor mutations, early in 2025.

The company also said chief business and financial officer Fang Ni is leaving the company as part of the restructuring, while Erika Jones, currently senior vice president of finance and principal accounting officer, was named principal financial officer.

Chief People Officer Elizabeth Montgomery is also leaving the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2473843677"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2473843677\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2473843677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 04:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473843677","market":"us","top_or_hot":-1,"title":"Black Diamond Cuts Programs, Workforce to Save Funding for Prospective Lung Cancer Therapy","media":"MT Newswires Live","content":"<html><body><p> Black Diamond <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BDTX) disclosed plans Monday to restructure business to focus on advancing its BDTX-1535 lead program candidate and extending its financial resources into Q2 2026.</p><p>Black Diamond said it expects to report initial results from phase 2 testing of BDTX-1535, a treatment for a form of recurrent non-small cell lung cancer characterized by epidermal growth factor receptor mutations, early in 2025.</p><p>The company also said chief business and financial officer Fang Ni is leaving the company as part of the restructuring, while Erika Jones, currently senior vice president of finance and principal accounting officer, was named principal financial officer.</p><p>Chief People Officer Elizabeth Montgomery is also leaving the company.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Black Diamond Cuts Programs, Workforce to Save Funding for Prospective Lung Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlack Diamond Cuts Programs, Workforce to Save Funding for Prospective Lung Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-08 04:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Black Diamond <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BDTX) disclosed plans Monday to restructure business to focus on advancing its BDTX-1535 lead program candidate and extending its financial resources into Q2 2026.</p><p>Black Diamond said it expects to report initial results from phase 2 testing of BDTX-1535, a treatment for a form of recurrent non-small cell lung cancer characterized by epidermal growth factor receptor mutations, early in 2025.</p><p>The company also said chief business and financial officer Fang Ni is leaving the company as part of the restructuring, while Erika Jones, currently senior vice president of finance and principal accounting officer, was named principal financial officer.</p><p>Chief People Officer Elizabeth Montgomery is also leaving the company.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BDE","symbol_name":"黑钻","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2473843677","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473843677","pubTimestamp":1728334190,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Black Diamond Therapeutics  disclosed plans Monday to restructure business to focus on advancing its BDTX-1535 lead program candidate and extending its financial resources into Q2 2026.Black Diamond said it expects to report initial results from phase 2 testing of BDTX-1535, a treatment for a form of recurrent non-small cell lung cancer characterized by epidermal growth factor receptor mutations, early in 2025.The company also said chief business and financial officer Fang Ni is leaving the company as part of the restructuring, while Erika Jones, currently senior vice president of finance and principal accounting officer, was named principal financial officer.Chief People Officer Elizabeth Montgomery is also leaving the company.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BDE":"黑钻","BDTX":"Black Diamond Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"黑钻石削减项目和劳动力，为预期肺癌治疗节省资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDE":1,"BDTX":0.9},"content_text":"Black Diamond Therapeutics (BDTX) disclosed plans Monday to restructure business to focus on advancing its BDTX-1535 lead program candidate and extending its financial resources into Q2 2026.Black Diamond said it expects to report initial results from phase 2 testing of BDTX-1535, a treatment for a form of recurrent non-small cell lung cancer characterized by epidermal growth factor receptor mutations, early in 2025.The company also said chief business and financial officer Fang Ni is leaving the company as part of the restructuring, while Erika Jones, currently senior vice president of finance and principal accounting officer, was named principal financial officer.Chief People Officer Elizabeth Montgomery is also leaving the company.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}